Total Payments
$1,917
2023 Payments
$112.21
Companies
31
Transactions
94
Medicare Patients
3,492
Medicare Billing
$496,748
Payment Breakdown by Category
Food & Beverage$1,772 (92.4%)
Education$144.81 (7.6%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $1,772 | 84 | 92.4% |
| Education | $144.81 | 10 | 7.6% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| PFIZER INC. | $216.25 | 8 | $0 (2023) |
| Genentech USA, Inc. | $190.79 | 5 | $0 (2018) |
| GENZYME CORPORATION | $184.12 | 9 | $0 (2023) |
| Novartis Pharmaceuticals Corporation | $147.71 | 9 | $0 (2020) |
| Celgene Corporation | $131.38 | 7 | $0 (2018) |
| Kite Pharma, Inc. | $122.30 | 1 | $0 (2018) |
| E.R. Squibb & Sons, L.L.C. | $116.95 | 7 | $0 (2023) |
| Allergan Inc. | $107.40 | 1 | $0 (2019) |
| Seagen Inc. | $67.64 | 3 | $0 (2022) |
| Amgen Inc. | $60.98 | 3 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2023 | $112.21 | 5 | GENZYME CORPORATION ($45.34) |
| 2022 | $142.90 | 7 | GENZYME CORPORATION ($75.26) |
| 2021 | $96.61 | 5 | GENZYME CORPORATION ($63.52) |
| 2020 | $45.51 | 3 | Novartis Pharmaceuticals Corporation ($21.84) |
| 2019 | $236.10 | 10 | Allergan Inc. ($107.40) |
| 2018 | $623.76 | 34 | Kite Pharma, Inc. ($122.30) |
| 2017 | $659.46 | 30 | Genentech USA, Inc. ($154.69) |
All Payment Transactions
94 individual payment records from CMS Open Payments — Page 1 of 4
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/02/2023 | ABBVIE INC. | VENCLEXTA (Drug) | Food and Beverage | In-kind items and services | $24.04 | General |
| Category: ONCOLOGY | ||||||
| 08/08/2023 | PFIZER INC. | IBRANCE (Drug) | Education | In-kind items and services | $25.00 | General |
| Category: ONCOLOGY | ||||||
| 06/30/2023 | GENZYME CORPORATION | SARCLISA (Biological) | Food and Beverage | In-kind items and services | $21.30 | General |
| Category: Oncology | ||||||
| 05/10/2023 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $17.83 | General |
| Category: Oncology | ||||||
| 05/05/2023 | GENZYME CORPORATION | SARCLISA (Biological) | Food and Beverage | In-kind items and services | $24.04 | General |
| Category: Oncology | ||||||
| 11/07/2022 | Seagen Inc. | ADCETRIS (Biological) | Education | In-kind items and services | $26.22 | General |
| Category: Oncology | ||||||
| 09/21/2022 | GENZYME CORPORATION | SARCLISA (Biological), ELITEK | Food and Beverage | In-kind items and services | $17.22 | General |
| Category: Oncology | ||||||
| 09/08/2022 | GENZYME CORPORATION | ELITEK (Biological), SARCLISA | Food and Beverage | In-kind items and services | $12.81 | General |
| Category: Oncology | ||||||
| 05/27/2022 | Seagen Inc. | TUKYSA (Drug) | Food and Beverage | In-kind items and services | $21.33 | General |
| Category: Oncology | ||||||
| 05/11/2022 | GENZYME CORPORATION | SARCLISA (Biological), ELITEK | Food and Beverage | In-kind items and services | $22.15 | General |
| Category: Oncology | ||||||
| 05/10/2022 | GENZYME CORPORATION | SARCLISA (Biological), ELITEK | Food and Beverage | In-kind items and services | $23.08 | General |
| Category: Oncology | ||||||
| 05/09/2022 | Seagen Inc. | TUKYSA (Drug) | Food and Beverage | In-kind items and services | $20.09 | General |
| Category: Oncology | ||||||
| 11/16/2021 | GENZYME CORPORATION | ELITEK (Biological), SARCLISA | Food and Beverage | In-kind items and services | $17.41 | General |
| Category: Oncology | ||||||
| 07/26/2021 | GENZYME CORPORATION | SARCLISA (Biological) | Food and Beverage | In-kind items and services | $21.89 | General |
| Category: Oncology | ||||||
| 06/15/2021 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $13.85 | General |
| Category: Oncology | ||||||
| 05/25/2021 | Gilead Sciences, Inc. | Trodelvy (Drug) | Food and Beverage | In-kind items and services | $19.24 | General |
| Category: ONC | ||||||
| 05/10/2021 | GENZYME CORPORATION | ELITEK (Biological), SARCLISA | Food and Beverage | In-kind items and services | $24.22 | General |
| Category: Oncology | ||||||
| 09/03/2020 | Secura Bio, Inc. | Farydak (Drug) | Food and Beverage | Cash or cash equivalent | $7.18 | General |
| Category: Oral Oncologic | ||||||
| 02/28/2020 | Amgen Inc. | KANJINTI (Biological), MVASI, Neulasta | Food and Beverage | In-kind items and services | $16.49 | General |
| Category: Oncology | ||||||
| 01/30/2020 | Novartis Pharmaceuticals Corporation | MEKINIST (Drug), TAFINLAR | Food and Beverage | In-kind items and services | $21.84 | General |
| Category: ONCOLOGY | ||||||
| 11/21/2019 | Novartis Pharmaceuticals Corporation | MEKINIST (Drug), TAFINLAR | Food and Beverage | In-kind items and services | $18.37 | General |
| Category: ONCOLOGY | ||||||
| 10/15/2019 | Allergan Inc. | NATRELLE (Device) | Food and Beverage | In-kind items and services | $107.40 | General |
| Category: PLASTICS | ||||||
| 10/09/2019 | PFIZER INC. | XTANDI (Drug) | Education | In-kind items and services | $11.50 | General |
| Category: ONCOLOGY | ||||||
| 09/23/2019 | Janssen Biotech, Inc. | DARZALEX (Biological) | Food and Beverage | In-kind items and services | $14.79 | General |
| Category: Oncology | ||||||
| 07/09/2019 | Novartis Pharmaceuticals Corporation | MEKINIST (Drug), TAFINLAR | Food and Beverage | In-kind items and services | $14.64 | General |
| Category: ONCOLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 8 | 627 | 1,207 | $237,935 | $93,253 |
| 2022 | 9 | 756 | 1,402 | $270,809 | $117,190 |
| 2021 | 11 | 747 | 1,462 | $258,068 | $129,739 |
| 2020 | 12 | 1,362 | 3,175 | $322,820 | $156,566 |
Total Patients
3,492
Total Services
7,246
Medicare Billing
$496,748
Procedure Codes
40
All Medicare Procedures & Services
40 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 227 | 497 | $95,930 | $36,753 | 38.3% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 96 | 267 | $70,648 | $29,356 | 41.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 187 | 263 | $35,768 | $12,248 | 34.2% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 23 | 42 | $7,476 | $3,961 | 53.0% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 31 | 61 | $7,564 | $3,824 | 50.6% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 27 | 27 | $11,016 | $3,435 | 31.2% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 17 | 19 | $7,239 | $2,498 | 34.5% |
| 99231 | Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes | Facility | 2023 | 19 | 31 | $2,294 | $1,178 | 51.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 241 | 521 | $98,990 | $39,972 | 40.4% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 101 | 233 | $61,512 | $26,804 | 43.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 239 | 349 | $46,244 | $17,283 | 37.4% |
| G9678 | Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a | Office | 2022 | 22 | 75 | $12,000 | $11,968 | 99.7% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 55 | 55 | $22,440 | $8,135 | 36.3% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 31 | 71 | $12,638 | $5,427 | 42.9% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 25 | 27 | $9,693 | $4,278 | 44.1% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 26 | 43 | $5,332 | $2,455 | 46.0% |
| 99231 | Follow-up hospital inpatient care per day, typically 15 minutes | Facility | 2022 | 16 | 28 | $1,960 | $868.47 | 44.3% |
| G9678 | Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a | Office | 2021 | 37 | 222 | $35,520 | $36,026 | 101.4% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 182 | 433 | $79,312 | $33,354 | 42.1% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 88 | 211 | $52,977 | $24,217 | 45.7% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 286 | 420 | $52,845 | $20,781 | 39.3% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 38 | 38 | $15,117 | $5,459 | 36.1% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 27 | 40 | $7,318 | $3,338 | 45.6% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2021 | 21 | 22 | $5,168 | $2,417 | 46.8% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 26 | 31 | $3,844 | $1,815 | 47.2% |
About Dr. Craig Franzman, MD
Dr. Craig Franzman, MD is a Hematology & Oncology healthcare provider based in Chesapeake, Virginia. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/19/2006. The National Provider Identifier (NPI) number assigned to this provider is 1477518827.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Craig Franzman, MD has received a total of $1,917 in payments from pharmaceutical and medical device companies, with $112.21 received in 2023. These payments were reported across 94 transactions from 31 companies. The most common payment nature is "Food and Beverage" ($1,772).
As a Medicare-enrolled provider, Franzman has provided services to 3,492 Medicare beneficiaries, totaling 7,246 services with total Medicare billing of $496,748. Data is available for 4 years (2020–2023), covering 40 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Chesapeake, VA
- Active Since 04/19/2006
- Last Updated 11/27/2013
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1477518827
Products in Payments
- IBRANCE (Drug) $154.64
- SARCLISA (Biological) $129.68
- Yescarta (Drug) $122.30
- Avastin (Biological) $120.82
- OPDIVO (Biological) $116.95
- NATRELLE (Device) $107.40
- Revlimid (Drug) $101.19
- ADCETRIS (Biological) $75.38
- MEKINIST (Drug) $68.08
- XARELTO (Drug) $55.50
- ELITEK (Biological) $54.44
- KEYTRUDA (Biological) $53.12
- AFINITOR (Drug) $45.78
- XTANDI (Drug) $43.63
- Perjeta (Biological) $43.51
- TUKYSA (Drug) $41.42
- Imbruvica (Drug) $36.39
- TASIGNA (Drug) $33.85
- BENDEKA (Drug) $30.83
- Abraxane (Drug) $30.19
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Chesapeake
William Maclaughlin, Md, MD
Hematology & Oncology — Payments: $4,512
Hematology & Oncology $4,512
Amy Skorupa, Md, MD
Hematology & Oncology — Payments: $3,783
Hematology & Oncology $3,783
Michail Alevizakos, Md, MD
Hematology & Oncology — Payments: $421.68
Hematology & Oncology $421.68
Cristina Alencar, M.d, M.D
Hematology & Oncology — Payments: $272.82
Hematology & Oncology $272.82
William Clark, Md, MD
Hematology & Oncology — Payments: $87.50
Hematology & Oncology $87.50